Skip to main content

Ebanga FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 25, 2021.

FDA Approved: Yes (First approved December 21, 2020)
Brand name: Ebanga
Generic name: ansuvimab-zykl
Dosage form: Injection
Company: Ridgeback Biotherapeutics, LP.
Treatment for: Zaire Ebolavirus Infection

Ebanga (ansuvimab-zykl) is a monoclonal antibody for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children.

Development timeline for Ebanga

Dec 21, 2020Approval FDA Approves Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection
Aug 28, 2020Ridgeback Biotherapeutics LP Announces Initiation of Expanded Access Protocol for Ebola Treatment Ansuvimab
Jul 29, 2020Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for Ansuvimab Ebola Treatment

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.